STE

Company Overview: STERIS plc, valued at $21.7 billion, specializes in infection prevention and healthcare products, experiencing a 10.1% drop from its 52-week high but showing a 6.2% increase over the past three months, outperforming the Dow Jones Industrials Average.

Financial Performance: Following strong Q3 2025 results with adjusted EPS of $2.32 and positive growth in key segments, analysts maintain a "Strong Buy" rating for STE, which is currently trading below the mean price target of $256.67.

Jim Cramer's Recommendations: On CNBC's "Mad Money," Jim Cramer advised selling NANO Nuclear Energy and expressed skepticism about Illumina, while recommending buying stocks in STERIS, Lam Research, and Arista Networks, which have received positive analyst ratings.

Stock Performance Overview: Recent stock performance showed declines for Illumina, Archer Aviation, Sixth Street Specialty Lending, Lam Research, and Arista Networks, while NANO Nuclear Energy shares gained slightly.

Company Overview: DexCom, Inc., a large-cap medical device company based in San Diego, specializes in continuous glucose monitoring systems for diabetes management, boasting a market cap of $27.6 billion but has seen its stock decline significantly over the past year.

Stock Performance and Analyst Outlook: Despite recent underperformance and missing earnings estimates, analysts maintain a "Strong Buy" consensus on DexCom's stock, with a mean price target suggesting a potential 46.9% increase from current levels.

Settlement Agreements: Steris' subsidiary, Isomedix Operations, has entered into binding term sheets and settlement agreements to resolve most personal injury claims related to ethylene oxide in Cook County, Illinois, with a potential payout of up to $48.15 million.

Stock Market Reaction: Following the announcement, Steris shares increased by 2% to $227.52, reflecting positive investor sentiment despite the ongoing legal issues.

Analyst Rating on Steris: Jason Bednar from Piper Sandler has maintained a Buy rating on Steris with a price target of $265.00, while the current analyst consensus is a Moderate Buy.

Stock Performance Overview: Steris shares closed at $222.72, with a one-year high of $248.24 and a low of $197.82, alongside an average volume of 499K.

Company Overview and Performance: STERIS plc, a $22 billion company based in Mentor, Ohio, specializes in infection prevention products but has underperformed the market, with a 5.1% decline over the past year compared to a 17% rise in the S&P 500. However, it has seen an 8.9% increase in 2025, outperforming the SPX.

Analyst Ratings and Future Outlook: Despite recent challenges, including a revenue miss in Q3, analysts maintain a "Strong Buy" consensus on STE stock, with price targets suggesting potential upside of 14.7% to 18.4%.

Analyst Ratings Overview: Recent evaluations of Steris by four analysts show a mix of bullish and bearish sentiments, with the average 12-month price target rising slightly to $258.75, reflecting a positive outlook despite some challenges in revenue growth and profitability metrics.

Company Financials: Steris, a leader in sterilization services, has reported a revenue growth rate of 7.33% over the last three months, but its net margin, return on equity, and return on assets are below industry averages, indicating potential financial management issues.

Analyst Rating and Stock Performance: Michael Matson from Needham has maintained a Hold rating on Steris, with the stock currently priced at $221.46, while the analyst consensus suggests a Moderate Buy with an average price target of $253.33.

Insider Activity and Sentiment: Recent insider activity shows a negative sentiment towards Steris, with 55 insiders selling shares, including a significant sale by SVP Cary L Majors, indicating a potential lack of confidence in the company's future performance.

Kura Oncology Analysis: Analysts maintain a bullish outlook on Kura Oncology, with JMP Securities setting a Buy rating and a price target of $28.00, indicating a potential upside of 209.1% from current levels.

Steris Performance: Steris also receives a Buy rating from JMP Securities, with a price target of $265.00, suggesting a moderate buy consensus and a 14.7% upside from its recent closing price.

Financial Performance: STERIS plc reported a 6% increase in total revenue from continuing operations for the third quarter of fiscal 2025, reaching $1.4 billion, with diluted EPS rising to $1.75 and adjusted EPS to $2.32. Healthcare revenue grew by 7%, while Applied Sterilization Technologies saw a 10% increase, though Life Sciences revenue decreased by 7%.

Updated Fiscal Outlook: The company has revised its fiscal 2025 revenue growth expectations to approximately 6%, down from previous estimates of 6.5% to 7.5%, primarily due to unfavorable currency rates and lower anticipated capital equipment revenue in the Healthcare segment. Adjusted earnings per share are now expected to be between $9.05 and $9.15.

Earnings Performance: STERIS plc reported a third-quarter profit of $173.53 million ($1.75 per share), an increase from $140.74 million ($1.42 per share) last year, aligning with analyst expectations for adjusted earnings of $2.32 per share.

Revenue Growth: The company's revenue rose by 5.6% to $1.370 billion compared to $1.297 billion in the previous year, with full-year EPS guidance set between $9.05 and $9.15.

Analyst Rating and Price Target: Jason Bednar from Piper Sandler maintains a Buy rating on Steris with a price target of $265, while the stock closed at $220.65 last Friday. The general analyst consensus suggests a Moderate Buy rating with an average price target of $253.33.

Company Performance and Insider Activity: Steris reported quarterly revenue of $1.33 billion and a net profit of $150.03 million, showing growth compared to the previous year. However, insider sentiment is negative, with an increase in share sales by insiders, including a recent sale by SVP Cary L Majors.

Price Target Update: Piper Sandler has increased the price target for Steris (STE) from $260 to $265 while maintaining an Overweight rating, indicating a solid performance expected from Steris' healthcare franchise.

Investment Insights: TipRanks offers tools like Smart Score to help investors identify top-performing stocks and compare their picks with recommendations from leading Wall Street analysts.

Quarterly Dividend Announcement: STERIS plc announced a quarterly interim dividend of $0.57 per share, payable on March 21, 2025, to shareholders recorded by February 20, 2025.

Forward-Looking Statements Caution: The company issued a cautionary statement regarding forward-looking information, highlighting various risks and uncertainties that could affect its performance and financial results.

Mistrial Announcement: A jury trial against Isomedix Operations, a subsidiary of STERIS plc, ended in a mistrial due to the dismissal of a juror, with plans for a retrial regarding claims of personal injury linked to ethylene oxide emissions from a sterilization facility in Illinois.

Company's Defense and Practices: Isomedix intends to vigorously defend itself against the allegations and emphasizes its commitment to environmental standards through regular investments and adherence to best practices at its facilities.

STERIS plc Options Trading: STERIS plc experienced significant options trading with 2,188 contracts, particularly for the $210 strike put option expiring on February 21, 2025, which saw 1,500 contracts traded.

TJX Companies Options Trading: TJX Companies had a high options trading volume of 22,969 contracts, notably for the $130 strike call option expiring on February 21, 2025, with 5,521 contracts traded.

Earnings Expectations: STERIS plc is set to announce its third-quarter earnings on February 5, with analysts predicting a non-GAAP profit of $2.32 per share, reflecting a 4.5% increase from the previous year. The company has consistently met or exceeded Wall Street's expectations in recent quarters.

Stock Performance and Analyst Ratings: Despite a 7.2% decline in stock value over the past year, STERIS holds a "Strong Buy" consensus rating among analysts, with a mean price target suggesting a potential upside of 23.4%. The company's effective expense management led to a significant increase in net income, despite mixed Q2 results.

Company Overview and Market Performance: STERIS plc, a Mentor, Ohio-based company with a market cap of $20.7 billion, provides infection prevention products and services globally but has seen its stock decline significantly, dropping 16.6% from its 52-week high and underperforming compared to the Nasdaq Composite.

Financial Results and Analyst Outlook: Despite mixed Q2 results showing revenue growth but declining gross margins, STERIS managed to exceed adjusted EPS estimates; analysts maintain a "Strong Buy" rating with a price target suggesting a potential upside of 23.6%.

STERIS PLC Stock Analysis: STERIS PLC (STE) is rated 62% by Validea's Growth Investor model, which focuses on growth stocks with strong earnings and sales growth, reasonable valuations, and low debt. A score above 80% indicates interest in the stock, while above 90% suggests strong interest.

About Martin Zweig: Martin Zweig, whose strategy is used for analyzing STE, had a successful investment newsletter that returned an average of 15.9% annually over 15 years, and he is known for his significant wealth and unique collectibles.

Company Overview: STERIS plc, valued at $21.3 billion, specializes in infection prevention and surgical support products, but its stock has underperformed compared to the broader market and healthcare sector over the past year.

Earnings Performance and Analyst Ratings: Despite a 7.3% revenue increase in Q2 and positive earnings surprises, STE's shares fell 5.3%. Analysts maintain a "Strong Buy" consensus rating, with price targets suggesting significant upside potential.